


**CLAIM LISTING**

Claims 1-25 (canceled)

26. (New) A stabilized oral pharmaceutical formulation comprising:

- (a) a nucleus formed by a core;
- (b) a first layer that comprises a polymer coating sealing the core and optionally one or more hydrophobic excipients; and
- (c) a second layer coating the first layer, wherein said second layer comprises one or more compounds of Formula I:



wherein :

A is -NH-, -CH<sub>2</sub>-, or -OCH<sub>2</sub>-;

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are each independently in each occurrence hydrogen, (C<sub>1</sub>-C<sub>6</sub>) alkyl, or halogen;

R<sup>6</sup> is (C<sub>1</sub>-C<sub>6</sub>) alkyl;

R<sup>2</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>) alkyl; or

R<sup>2</sup> and R<sup>3</sup> taken together with the atoms to which they are attached may form a 5- or 6-membered ring;

or pharmaceutically acceptable salts thereof.

27. The pharmaceutical formulation of Claim 26, wherein A is -OCH<sub>2</sub>-, R<sup>1</sup> and R<sup>6</sup> are methyl, R<sup>3</sup> is chloro, and R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen.

28. The pharmaceutically composition of Claim 26, wherein said compound in said second layer is *N*-[6-chloro-3-(4,5-dihydro-1*H*-imidazol-2-ylmethoxy)-2-methyl-phenyl]-methanesulfonamide.

29. (New) The pharmaceutical formulation of claim 26, wherein said second layer further comprises one or more acceptable hydrophobic excipients.

30. (New) The pharmaceutical formulation of claim 27, wherein the polymer coating comprises an enteric polymer.

31. The pharmaceutical formulation of Claim 30, wherein the polymer coating comprises shellac or methacrylic acid esters.


32. The pharmaceutical formulation of Claim 26, further comprising a third layer coating the second layer, wherein the third layer is an enteric polymer.

33. A process for the formulation of a stable oral pharmaceutical formulation, which process comprises:

(a) coating a core with a first layer sealing the core, wherein said first layer comprises an enteric polymer layer optionally comprising one or more hydrophobic excipients in an non-aqueous solvent.

(b) drying the first layer;

(c) coating the first layer with a second layer, wherein said second layer comprises one or more compounds of Formula I:



wherein :

A is -NH-, -CH<sub>2</sub>-, or -OCH<sub>2</sub>-;

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are each independently in each occurrence hydrogen, (C<sub>1</sub>-C<sub>6</sub>) alkyl, or halogen;

R<sup>6</sup> is (C<sub>1</sub>-C<sub>6</sub>) alkyl;

R<sup>2</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>) alkyl; or

R<sup>2</sup> and R<sup>3</sup> taken together with the atoms to which they are attached may form a 5- or 6-membered ring;

or pharmaceutically acceptable salts thereof;

said one or more compounds suspended in one or more acceptable hydrophobic excipients;

- (d) drying the second layer;
- (e) optionally coating the second layer with a third layer, wherein said third layer comprises an enteric polymer in a non-aqueous solvent, and
- (f) drying the third layer.

34. The process of Claim 33, wherein A is -OCH<sub>2</sub>-, R<sup>1</sup> and R<sup>6</sup> are methyl, R<sup>3</sup> is chloro, and R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are hydrogen.

35. The process of Claim 33, wherein said compound in said second layer is *N*-[6-chloro-3-(4,5-dihydro-1*H*-imidazol-2-ylmethoxy)-2-methyl-phenyl]-methanesulfonamide.